DTIL Logo

Precision BioSciences, Inc. (DTIL) 

NASDAQ
Market Cap
$63.82M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
525 of 776
Rank in Industry
284 of 433

Largest Insider Buys in Sector

DTIL Stock Price History Chart

DTIL Stock Performance

About Precision BioSciences, Inc.

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute …

Insider Activity of Precision BioSciences, Inc.

Over the last 12 months, insiders at Precision BioSciences, Inc. have bought $0 and sold $131,927 worth of Precision BioSciences, Inc. stock.

On average, over the past 5 years, insiders at Precision BioSciences, Inc. have bought $94,066 and sold $1.97M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 90,000 shares for transaction amount of $43,200 was made by Kelly John Alexander (Chief Financial Officer) on 2023‑08‑18.

List of Insider Buy and Sell Transactions, Precision BioSciences, Inc.

2024-11-04SalePresident and CEO
3,012
0.0412%
$8.19$24,668+1.59%
2024-11-04SaleGeneral Counsel and Secretary
588
0.008%
$8.19$4,816+1.59%
2024-06-10SaleChief Research Officer
50
0.0007%
$11.79$590-21.56%
2024-06-10SaleGeneral Counsel and Secretary
93
0.0013%
$11.79$1,096-21.56%
2024-05-02SaleChief Research Officer
154
0.0021%
$10.32$1,589-8.39%
2024-05-02SalePresident and CEO
1,526
0.021%
$10.32$15,748-8.39%
2024-05-02SaleGeneral Counsel and Secretary
272
0.0037%
$10.32$2,807-8.39%
2024-05-02SaleChief Medical Officer
290
0.004%
$10.32$2,993-8.39%
2024-05-01SaleGeneral Counsel and Secretary
918
$0$0-5.20%
2024-04-30SaleChief Medical Officer
238
0.0033%
$10.03$2,386-4.61%
2024-01-23SaleChief Research Officer
28,000
0.0231%
$0.37$10,360+2700.11%
2024-01-22SalePresident and CEO
137,390
0.1111%
$0.36$49,460+2696.34%
2024-01-22SaleGeneral Counsel and Secretary
21,287
0.0172%
$0.36$7,663+2696.34%
2024-01-22SaleChief Medical Officer
21,526
0.0174%
$0.36$7,749+2696.34%
2023-11-03SalePresident and CEO
125,025
0.1021%
$0.40$50,010+2183.83%
2023-11-03SaleGeneral Counsel and Secretary
16,023
0.0131%
$0.40$6,409+2183.83%
2023-08-18PurchaseChief Financial Officer
90,000
0.0791%
$0.48$43,200+1.94%
2023-06-08SaleGeneral Counsel and Secretary
13,361
0.0119%
$0.75$10,021-30.52%
2023-04-27SaleChief Medical Officer
7,771
0.0067%
$0.79$6,139-35.85%
2023-03-22SalePresident and CEO
46,999
0.0438%
$0.82$38,539-33.50%

Insider Historical Profitability

<0.0001%
FMR LLC
3738248
48.7318%
$8.3210<0.0001%
Kelly John AlexanderChief Financial Officer
383340
4.9972%
$8.3260<0.0001%
YAO TONY DUNG LINGdirector
158003
2.0597%
$8.3210<0.0001%
venBio Global Strategic Fund, L.P.director
50000
0.6518%
$8.3210<0.0001%
Heery ChristopherChief Medical Officer
2485
0.0324%
$8.3210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Tang Capital Management, LLC$7.99M8.51589,569-82.66%-$38.11M0.03
Janus Henderson$7.74M8.27573,052New+$7.74M<0.01
Perceptive Advisors$6.52M6.94480,483New+$6.52M<0.01
Spyglass Capital Management LLC$5.23M5.57385,440New+$5.23M3.92
The Vanguard Group$3.54M3.77260,831-94.51%-$60.94M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.